Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.34 |
| ▸ | SLC2A4 | P14672 | 3/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515904 | 0.86 | CYP11B1 (0.35) | KDM4EKDM5AKDM5BARCYP11B1 | |
| SCHEMBL3412105 | 0.83 | KDM4E (0.39) | KDM4ELMNAHTTKDM5AKDM5B | |
| SCHEMBL3416155 | 0.80 | KDM4E (0.39) | KDM4ELMNAHTTKDM5AKDM5B | |
| SCHEMBL3416157 | 0.80 | KDM4E (0.39) | KDM4ELMNAHTTKDM5AKDM5B | |
| SCHEMBL3411955 | 0.78 | HTR2A (0.38) | TP53THRBTDP1MEN1KMT2A | |
| SCHEMBL3413163 | 0.73 | CA12 (0.41) | KDM4ELMNAHTTTP53THRB | |
| SCHEMBL3416714 | 0.68 | CYP11B1 (0.36) | KDM4ECYP11B1CYP11B2EGLN2TDP1 | |
| SCHEMBL3416525 | 0.67 | CYP11B1 (0.35) | KDM4ELMNAHTTTP53CYP11B1 | |
| SCHEMBL3416520 | 0.67 | CYP11B1 (0.35) | KDM4ELMNAHTTTP53CYP11B1 | |
| SCHEMBL4308928 | 0.67 | AR (0.53) | KDM4ELMNAHTTARSLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
| EP-2265611-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009112832-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP11 | KDM4E 3834/4885LMNA 504/4885HTT 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.